California Department of Public Health
Immunization Updates for Providers

Friday, March 8, 2024
9:00AM – 10:30AM
Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.

Resource links will be dropped into, “Chat”

Note: CDPH SMEs and Panelists on today’s call will do their best to answer all questions related to today’s updates.
Housekeeping

Reminder to Panelists:

Please mute yourself when not speaking.
Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:

Today’s session is being recorded. For slides, webinar recordings, and other postings, see the [CDPH Weekly Immunization Updates for Providers](#).

To be added to the CDPH email messaging listserv for providers, please email your request to [billiedawn.greenblatt@cdph.ca.gov](mailto:billiedawn.greenblatt@cdph.ca.gov)

If you have post-webinar-related questions, please email [leslie.amani@cdph.ca.gov](mailto:leslie.amani@cdph.ca.gov)
<table>
<thead>
<tr>
<th>No.</th>
<th>Item</th>
<th>Speaker(s)</th>
<th>Time (AM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Welcome, Announcements, and Poll</td>
<td>Leslie Amani and Cecilia Sandoval (CDPH)</td>
<td>9:00 – 9:05</td>
</tr>
<tr>
<td>2</td>
<td>COVID-19 Vaccine Administration Data</td>
<td>Celeste Romano (CDPH)</td>
<td>9:05 – 9:10</td>
</tr>
<tr>
<td>3</td>
<td>COVID-19 Testing Updates</td>
<td>Stefanie Medlin (CDPH)</td>
<td>9:10 – 9:15</td>
</tr>
<tr>
<td>4</td>
<td>Clinical Updates</td>
<td>Caterina Liu, MD (CDPH)</td>
<td>9:15 – 9:25</td>
</tr>
<tr>
<td>5</td>
<td>Therapeutics Update</td>
<td>Edward Salaguinto, PharmD, RPh (CDPH)</td>
<td>9:25 – 9:30</td>
</tr>
<tr>
<td>6</td>
<td>Vaccines for Children (VFC)</td>
<td>Christina Sapad (CDPH)</td>
<td>9:30 – 9:40</td>
</tr>
<tr>
<td>7</td>
<td>Vaccine Management</td>
<td>Amy Pine (My Turn) and Maria Volk (myCAvax)</td>
<td>9:40 – 9:50</td>
</tr>
<tr>
<td>8</td>
<td>Vaccines for Adults (VFA)</td>
<td>Lindsay Reynoso (CDPH)</td>
<td>9:50 – 9:55</td>
</tr>
<tr>
<td>9</td>
<td>Resources and Q&amp;A</td>
<td>Leslie Amani (CDPH)</td>
<td>9:55 – 10:30</td>
</tr>
</tbody>
</table>

**Thank you!**
Announcements

Leslie Amani, CDPH
Change: Provider Webinar Cadence

The CDPH Immunization Updates for Providers Webinar series is beginning a new cadence! The Friday webinars will move to a biweekly (every other Friday) cadence.

Meeting today Friday, March 8, 2024, from 9AM – 10:30AM
Next session: Friday, March 22, 2024, from 9AM – 10:30AM

Please continue to use the CDPH Immunization Updates for Providers Zoom Registration Link to join the sessions.

CDPH appreciates your continued attendance. Thank you for all that you are doing for the health and wellness of all Californians!
Sesame Care: COVID-19 Vaccine Appointments

The California COVID-19 telehealth program through Sesame Care officially ended on Thursday, February 29, 2024.

Sesame Care in partnership with CDPH will be offering $30 COVID-19 vaccine appointments for California residents.

Visit [https://sesamecare.com/covidca](https://sesamecare.com/covidca) and use the promo code **CACOVID** to get the discounted rate.
**Respiratory Syncytial Virus (RSV) Vaccine Fact Sheet**

### Vaccine Fact Sheet: Respiratory Syncytial Virus (RSV)

**Topic** | **AbbVie™** | **Arexy**
---|---|---
**Manufacturer** | Pfizer | GSK
**Product Info** | Detailed prescribing information | Detailed prescribing information
**Protections Against** | RSV | RSV
**Approved Ages** | - Individuals 60 years of age or older. | - Individuals 60 years of age or older.
| - Pregnant individuals at 32-36 weeks gestational age. | - Pregnant individuals at 32-36 weeks gestational age.
**Routine Schedule & Intervals** | One dose for individuals 60 years of age and older using shared clinical decision-making. | One dose for individuals 60 years of age and older using shared clinical decision-making.
**Administration** | MDI intramuscular injection | MDI intramuscular injection
**Packaging** | Supplied in a kit that includes: lyophilized antigen component, a prefilled syringe containing sterile water diluent component and a vial adapter. | Supplied in 3 vials that must be reconstituted prior to administration. (Lyophilized antigen component and adj. suspensions).
| Supplied in cartons of 1, 5, or 10 vials. | Supplied in carton of 10 doses.
**Dosage** | 0.5 mL single dose after reconstitution. | 0.5 mL single dose after reconstitution.
| 0.5 mL single dose after reconstitution. | 0.5 mL single dose after reconstitution.
**Storage** | Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton. | Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton.
**Preparation** | Prepare by reconstituting the lyophilized antigen component (a sterile white powder) with the accompanying prefilled syringe containing sterile water diluent component. Do not freeze. Discard if the contents have been frozen. | Prepare by reconstituting the lyophilized antigen component (a sterile white powder) with the accompanying lyophilized antigen component and adj. suspensions. Do not freeze. Discard if the contents have been frozen.

California Department of Public Health, Immunization Branch

---

**Respiratory Syncytial Virus (RSV) Vaccine Fact Sheet**

**Topic** | **AbbVie™** | **Arexy**
---|---|---
**Expiration Date** | 18 months from manufacture date | 18 months from manufacture date
**Full ACP Recommendations** | RSV Vaccine ACP Recommendations | RSV Vaccine ACP Recommendations
**VIS** | RSV, VXS | RSV, VXS
**Program Letter** | VSA letter | VSA letter
**Billing Codes** | ABN Code: 0471 | ABN Code: 0471
| MCRA code: 0078 | MCRA code: 0078
| See Existing Respiratory Vaccine Codes for more info. | See Existing Respiratory Vaccine Codes for more info.
**Comments** | Licensed in 2022 | Licensed in 2022

Refer to Vaccine Fact Sheets (EZIZ.org/Resources/VaccineFactSheets).

California Department of Public Health, Immunization Branch

This publication was supported by Grant number HHSN275201900014I from the Centers for Disease Control and Prevention (CDC). The contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC.
# Immunization Fact Sheet: RSV – nirsevimab (Beyfortus™)

## Immunization Fact Sheet: Respiratory Syncytial Virus (RSV)

### Topic: Nirsevimab (Beyfortus™)

**Manufacturer:** AstraZeneca and Sanofi

**Product Info:** Detailed prescribing information and links

**Products Against:** Respiratory Syncytial Virus (RSV)

**Approved Ages:**
- FDA licensed for:
  - Neonates and infants born during or entering their 1st RSV season.
  - Infants born before 24 months of age who remain vulnerable to severe RSV disease through their 2nd RSV season.

**Schedule & Intervals:**
- 1 dose for all infants born during or entering their 1st RSV season.
- The birth parent did not receive RSV vaccine during pregnancy.
- The birth parent’s RSV vaccination status is unknown.
- The infant was born within 14 days of parent’s RSV vaccination.

**Dose:**
- 1 dose for infants and children 6–18 months old entering their 2nd RSV season and who are at increased risk for severe RSV.
  - Native American/African Native children
  - Children with chronic lung disease or prematurity who require medical support (chronic cardiopulmonary, diaphragmatic, or supplemental oxygen) at any time during the 50th percentile period before the start of the second RSV season.
  - Children who are severely immunocompromised
  - Children with cystic fibrosis who have either:
    - Severe lung disease (genetically facilitated for pulmonary exacerbation in the first year of life or abnormalities on chest imaging at any time post diagnosis).
    - Weight-for-length that is <10th percentile.

**Administration:** Intramuscular injection.

**Packaging:**
- Pre-filled syringe:
  - 50 mg (SFM) with purple plunger rod for infants weighing <5 kg
  - 100 mg (SFM) with light blue plunger rod
- Cartons of five pre-filled syringes:
  - 60 mg (SFM) with single-dose pre-filled syringes in a carton
  - 150 mg (SFM) with single-dose pre-filled syringes in a carton
- Disposable needle: See instructions included.

**Dosage:**
- Age 6 months:
  - Weight <5 kg: 50 mg dose (purple plunger rod)
  - Weight 5–10 kg: 100 mg dose (light blue plunger rod)
- Age 6–11 months:
  - 200 mg dose (2 separate 100 mg injections, at the same time at different sites)

---

## Vaccine Fact Sheet: Respiratory Syncytial Virus (RSV) (Continued)

### Recommended Timing
- For infants born during RSV season: Within 3 weeks of birth. Infants with prolonged birth hospitalizations should receive nirsevimab shortly before or promptly after hospital discharge.
- For infants born outside of RSV season and children 6–19 months: Optimal administration is at the start of RSV season, usually October. Nirsevimab should be offered throughout the RSV season, typically October through March. For considerations of nirsevimab versus palivizumab for high-risk children, see Nirsevimab/Palivizumab Timing Guide.

### Storage
- Nirsevimab ships similarly to other pediatric routine vaccines.

- Routine storage: In a refrigerator at 2°C – 8°C. DO NOT FREEZE.
- Short-term storage: Room temperature (20°C – 25°C) for 8 hours, if protected from light.

### Use-by Limit
- Nirsevimab has a shelf life of about 18 months. Once removed from the refrigerator, must be used within 8 hours or discarded.

### Expiration Date
- See packaging for expiration info. Nirsevimab can be returned after expiration, similar to other Sanofi vaccines. See more for details.

### Full ACP Recommendations
- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children 1, MMWR
- VG: Information Immunization Statement

### Program Letter
- VFC Letter

### Billing Codes

### Comments
- Licensed in 2023

---

California Department of Public Health, Immunization Branch

This publication was supported by Grant Number 1UO1CE020558 from the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC.

### Immunization Fact Sheet: nirsevimab (Beyfortus™)

### EZIZ Resource: Vaccine Fact Sheets
The California Immunization Coalition invites you to attend the next CIC Ed Hour which will feature the amazing team of Lydia Greene and Heather Simpson, the co-founders of Back to the Vax. Heather and Lydia who will share their journey as parent advocates and their work to share their experiences with practitioners and public health partners across the country.

When: Monday, March 11, 2024
Time: 12PM, PT
Registration link: Back to the Vax Zoom Registration Link
The California Department of Public Health (CDPH) and many LHJs in California are working to be more inclusive of historically marginalized communities in their engagement and decision-making.

Building off of a recently-released research brief published by Onside Partners and ThinkForward Strategies in partnership with Blue Shield California Foundation, this webinar will explore what authentic community engagement by public agencies looks like and showcase inspiring examples from diverse California public health and education agencies that have successfully transformed their engagement strategies. These examples illustrate that meaningful change doesn’t necessarily demand vast resources but rather requires strong leadership and internal capacity building. We will hear from state and local public health practitioners about their equity-centered community engagement practices and what they see as the keys to success. Audience members will also have the opportunity to share their own community engagement practices and ask questions to the speakers. This webinar is sponsored and co-hosted by Blue Shield of California Foundation.

Speakers:
- Dr. Rohan Radhakrishna, Deputy Director, CA Department of Public Health, Office of Health Equity
- Karen Ben-Moshe, Program Officer, Blue Shield of California Foundation
- Christine Fry, Principal, Onside Partners
- Practitioner Speakers – To be announced

When: Tuesday, March 12, 2024
Time: 2PM – 3:15PM
Register: Equity-Centered Community Engagement by Public Health Departments: Lessons from the Field
CDPH Infection Prevention Webinars

The California Department of Public Health (CDPH)—with the California Association of Long Term Care Medicine (CALTCM), California Association of Health Facilities (CAHF), and Health Services Advisory Group (HSAG)—hosts a monthly (4th Wednesday) webinar on infection prevention for long-term care facilities to discuss any recent updates on Coronavirus Disease 2019 (COVID-19) and provide a venue for addressing questions. The webinars focus on infection prevention guidance for SNFs. It is recommended that SNF infection prevention staff attend. Local health departments and SNF administrators, directors of nursing, and medical directors are also encouraged to attend. Please register in advance; space is limited. A recording link will be available the day following the webinar.

**Day of the webinar event:** Call-in telephone number for all webinars is: **415.655.0003**. You may join via computer (using your computer or telephone for audio) or by telephone only. (If you join the video portion of the webinar, for a better webinar experience we recommend you have Webex call your phone—don’t dial in yourself.)

**Note:** The CDPH 2nd Tuesday all-facilities phone calls have been discontinued for 2024.

Register for Upcoming Webinars

**CDPH Infection Prevention Webinar**

3:00 PM - 4:00 PM | Mar 27, 2024 (UTC-08:00) | JoLynn Hinger

**CDPH Webinars Registration Link for Webex**

[Health Services Advisory Group (HSAG) Webinars](#)
June 2024 California Immunization Coalition Summit

Audience: Physicians, pharmacists, nurses, administrators, educators, immunization stakeholders, coalition members, advocates and other providers from the public and private sector who are involved in working on current immunization issues, strategies and activities.

Location: Sacramento, CA

The 2024 California Immunization Coalition Summit will provide clinical updates and the latest information on issues related to vaccine administration and communication. Participating in this statewide event will provide access to the latest information on immunization issues and communication strategies and will help connect you with public health colleagues and private sector representatives that can assist your work in educating and supporting your community. The Summit is a terrific opportunity to renew our collective vision to make access to vaccinations and disease prevention a reality for all Californians.

California Immunization Coalition Annual Summit Registration Link
Poll: CAIR Naming: COVID-19 Vaccine Group

Question: What should CAIR name the new COVID-19 vaccine group under the recommendations section of CAIR?

- COVID-19 Annual
- COVID-19 Seasonal
- COVID-19 Updated
COVID-19 Vaccine Administration Data

Celeste Romano, CDPH
COVID-19 Vaccine Administration Summary
as of March 4, 2024

95,439,976
Total Doses Administered:

Daily Doses Administered: Statewide

5,479,909
Total Up-to-Date* Recipients:

Percent of Population Who Are Up-to-Date

13.7%
Statewide

*Has received a dose of the Updated 2023-2024 vaccine

Public Dashboard Link
CDC - Updated 2023-2024 Formula mRNA Vaccine
Most Recent Eligibility Groups

- Additional Updated 2023-2024 dose for 65+ age group
Up-to-Date COVID-19 Vaccination Status Among 65+ by Race/Ethnicity*

as of March 4, 2024

Highest uptake among NHPI**, White, and AIAN**

Uptake above state average in all 65+ race/ethnicity groups

*Vaccination rate estimates for some groups, such as NHPI, may be affected by differences in how demographic data is collected by the Census and at the time of vaccination
**NHPI = Native Hawaiian and Pacific Islander, AIAN = American Indian or Alaska Native

CDC/ACIP Recommends Additional Dose for 65+
Up-to-Date COVID-19 Vaccination Status Among 65+
by HPI
as of March 4, 2024

Highest uptake among Healthy Places Index quartiles 3&4

Uptake above state average in all Healthy Places Index quartiles

CDC/ACIP Recommends Additional Dose for 65+
COVID-19 Vaccine Data Summary
as of March 4, 2024

Key Metrics

| 95.4 million doses administered | +51 thousand doses administered |
| 13.7% Statewide who are Up-to-Date | 5.5 million Up-to-Date recipients |
| 34.2% 65+ population Up-to-Date | 2.1 million 65+ Up-to-date recipients |

System Notes

- Public dashboard is not yet updated to include the latest 2023-2024 guidelines
  - Updated monthly
- Email cdphvaccinedatateam@cdph.ca.gov for questions and comments
COVID-19 Testing Updates
Stefanie Medlin, CDPH, Medical Countermeasures
COVID-19 Testing Updates

**CDPH At-Home Testing Program:** As of February 29, 2024, the CDPH At-Home Testing Program has come to an end and COVID-19 at-home tests are no longer available to request from CDPH.

**Professional CLIA-waived tests:** Professional tests available to facilities with their own CLIA-waiver and state facility license through June 30, 2024. Eligible facilities would be Skilled Nursing Facilities, Long-Term Care Facilities and Community Clinics.

BinaxNOW CLIA-waived tests have extended expiration dates through July 2024.

We have depleted our inventory of COVID/Flu A&B multiplex tests. Should these tests become available again, we will notify this group of their availability.

Order professional CLIA-waived tests here: [https://labsupport.powerappsportals.us/ordercovidprofessionaluse/](https://labsupport.powerappsportals.us/ordercovidprofessionaluse/)

For testing needs in an emergent scenario (outbreak etc.), please reach out to your local health department. Skilled Nursing Facilities and Long-Term Care Facilities may be eligible to receive tests through their local Medical Health Operational Area Coordinator (MHOAC). If you are an eligible facility, please contact your MHOAC for support: [MHOAC Contact List](#)
Additional Ways for Individuals to Obtain COVID-19 Tests

Insured? You may be eligible for tests. Read more here: https://covid19.ca.gov/get-tested/

Fall 2023, U.S. households can order free COVID-19 tests mailed to their home: https://www.covid.gov/tests *The LAST day to order tests through USPS is March 8, 2024. If you have not yet placed an order for tests through the federal government, since November 20, 2023, you have until the end of the day on March 8th to order. After March 8th, tests will no longer be available.

Home Test to Treat offers free tests and free treatment (if eligible) for COVID-19 at home www.test2treat.org. * As of December 8, 2023, eligible individuals that sign up for Home Test to Treat will be sent COVID/Flu tests to use and home treatment options available will include COVID and Flu treatment (depending on the test result).

For questions, email OTCTesting@cdph.ca.gov
Clinical Update
Caterina Liu, MD, CDPH
Advisory Committee on Immunization Practices (ACIP) Meeting: February 28 – 29, 2024

- Vaccine topics with votes
  - COVID-19
  - Chikungunya
  - VFC – Diphtheria, Tetanus, and Pertussis

- Other ACIP topics (no vote)
  - RSV vaccine
  - Influenza vaccine
  - Polio
  - Meningococcal
  - Pneumococcal
  - Vaxelis (combined DTaP, IPV, HIB, Hep B)

ACIP Meeting Presentations, February 28-29, 2024

ACIP Recent Meeting Recommendations

Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States
CDC Recommends COVID-19 Vaccine Additional Dose for Adults 65+

CDC recommends that persons ≥ 65 years of age should receive an additional dose of 2023-2024 COVID-19 vaccine, at least 4 months after previous updated (2023-2024) COVID-19 vaccine dose.

September 2023
- Updated 2023-2024 Vaccine (monovalent, XBB.1 component) recommended for all individuals 6 months+
- Recommendation for optional additional doses for all IC people

February 2024
- Recommendation for additional (second) dose for adults 65+

CDC Director Press Release, February 28, 2024
Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States
Guidance for Immunocompromised People

6 months-64 years

**May** receive additional updated doses 2 months following previous updated dose*

This guidance is unchanged

65+ years

**Should** receive 1 additional updated dose 2 months after previous updated dose*

This guidance is new

*Further additional doses may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances, at least 2 months after the last updated (2023–2024 Formula) COVID-19 vaccine dose.
Updated CDPH Timing Guide

English version
IMM 1396

Spanish version
IMM 1396S
Older Adults at Highest Risk of Severe COVID-19


Monthly rates of provisional COVID-19 deaths by age group, United States, January 1, 2023 – January 31, 2024
Summary

• COVID-19 hospitalizations peaked in late December/early January; however, there are still approximately 20,000 new hospital admissions and 2,000 deaths due to COVID-19 each week.

• Risk of severe illness due to COVID-19 continues throughout the year and is highest in those ≥65 years.

• Effectiveness of an additional dose in older adults has been demonstrated by past additional doses.

• Receipt of 2023-2024 COVID-19 vaccine provides protection against JN.1 and other circulating variants, however vaccine effectiveness is expected to wane and additional dose in adults ≥65 years may restore protection that has waned since a fall vaccine dose.

• Greatest benefit of a vaccine dose would be in those who have not yet received a 2023-2024 dose, particularly older adults and those with underlying medical conditions.
Looking Ahead: Revised Time Frame for 2024-2025 COVID-19 Vaccine Availability

COVID-19 vaccine policy and next steps (cdc.gov)
ACIP Vote – Chikungunya vaccine

• **November 2023**: FDA approval of IXCHIQ (chikungunya vaccine), indicated for individuals at increased risk of exposure to chikungunya (single dose for adults 18+).

• **February 2024**: ACIP recommendations
  
  • Chikungunya vaccine is recommended for persons aged ≥18 years traveling to a country or territory where there is a chikungunya outbreak.
  
  • In addition, chikungunya vaccine may be considered for the following persons traveling to a country or territory without an outbreak but with evidence of chikungunya virus transmission among humans within the last 5 years:
    
    • Persons aged >65 years, particularly those with underlying medical conditions, who are likely to have at least moderate exposure* to mosquitos, OR
    
    • Persons staying for a cumulative period of 6 months or more
    
    • Chikungunya vaccination is recommended for laboratory workers with potential for exposure to chikungunya virus.

*Moderate exposure could include travelers who might have at least 2 weeks (cumulative) of exposure to mosquitos in indoor and/or outdoor settings
ACIP VFC Vote - Diphtheria, Tetanus, Pertussis Vaccines

• Background
  • CDC recommends young children receive DTaP as the first dose in the diphtheria, tetanus, and pertussis childhood vaccination series (5 dose series)
  • For children <7 years who develop a contraindication to DTaP, CDC previously recommended DT instead of DTaP
    • DT vaccine is no longer available in the United States
    • New guidance: for young children with a contraindication to pertussis-containing vaccines, vaccine providers may administer Td for all recommended remaining doses in place of DTaP

• VFC resolution (vote):
  • The addition of Td vaccine for use in children < 7 years of age for whom receipt of the pertussis component is contraindicated.
  • Update the language regarding the Tdap booster to align with ACIP recommendations
Limited Td Supplies - CDC Guidance

• While Td vaccine supplies are constrained, providers should transition to use of Tdap vaccine in lieu of Td vaccine whenever possible, including when a tetanus booster is indicated for wound management.

• The limited supply of Td vaccine needs to be preserved for those with a specific contraindication to pertussis-containing vaccines.
  
  • (ACIP VFC Vote) For children <7 years who develop a contraindication to DTaP, vaccine providers may administer Td for all recommended remaining doses in place of DTaP

CDC Vaccines and Preventable Diseases (VPD): Diphtheria, Tetanus, and Pertussis Vaccine Recommendations
Respiratory Syncytial Virus (RSV) Updates

• Safety review of potential risk of Guillain Barre Syndrome (GBS) in older adults (60+)
  • Estimated benefits of RSV vaccination outweigh potential risks when vaccination is implemented using the current recommendation that adults aged ≥60 years may receive RSV vaccination, using shared clinical decision-making

• Timing considerations for RSV vaccine in older adults (60+)
  • For unvaccinated adults, the best time to get vaccinated is in the late summer or early fall

• Policy issues to be addressed in June 2024
  • Moderna mRNA-1345 vaccine for use in adults aged ≥60 years
  • GSK RSV vaccine for use in adults aged 50–59 years at increased risk for RSV disease
  • Consideration of whether shared clinical decision-making remains the preferred policy option
Other ACIP Topics

- **Influenza**
  - Vaccination with a 2023-24 influenza vaccine reduced the risk for influenza outpatient visits and hospitalizations among all age groups across 22 US states
  - Interim 2023-2024 vaccine effectiveness (VE) estimates from California public health data also show vaccine is protective
  - Various platforms and methods have yielded VE estimates for this season ranging from 45-67%

- **Meningococcal** – Considerations for revision of the adolescent meningococcal vaccine schedule
- **Pneumococcal** – New vaccine (PCV21) Phase 3 trials
- **Polio** – Discussion of potential use of novel type 2 oral poliovirus vaccine (nOPV2) as an outbreak control measure in the U.S.
- **Vaxelis** (combined DTaP, IPV, HIB, Hep B) – Considerations for use of Vaxelis in American Indian and Alaska Native infants
Therapeutics Update

Edward Salaguinto, PharmD, RPh, CDPH
Reminder: Paxlovid Emergency Use Authorization (EUA)

• On January 29, 2024, the FDA announced an important revision to the Paxlovid EUA stating that EUA-labeled Paxlovid distributed by the U.S. government will remain authorized for use only through March 8, 2024.

• After that date, all EUA-labeled Paxlovid needs to be returned or otherwise disposed.
  o www.PaxlovidEUAreturns.com
  o PaxlovidEUAreturns@inmar.com
  o call 877-740-6148

• The Paxlovid EUA will continue to authorize emergency use of the NDA-labeled Paxlovid for eligible pediatric patients 12 years of age and older weighing at least 88 pounds (40 kg).
Vaccines for Children (VFC)

Christina Sapad, CDPH
Limited Td Vaccine Supplies

- MassBiologics has discontinued production of TdVax™. Supply of TdVax™ is anticipated to last through June.
- Sanofi, manufacturer of Tenivac®, is taking steps to augment their available supply of Td for the US and will be implementing ordering controls until the supply has increased.
- It is anticipated that the supply of Td vaccine in the US market will be constrained through 2024.
- Temporary ordering controls are in place in the public and private sectors. As a result, CDC has put allocations into place for all three Td vaccine presentations (Grifols vials; Sanofi vials; and Sanofi syringes).
- **Due to the limited allocations, VFC providers can only request up to 10 doses of Td vaccine with your routine VFC vaccine order.**
- Tetanus, diphtheria, and acellular pertussis (Tdap) vaccines are available without supply constraints at this time.
Limited Td Supplies - CDC Guidance

- **Transition to use of Tdap** vaccine in lieu of Td vaccine whenever possible **while Td vaccine supplies are constrained**, including when a tetanus booster is indicated for wound management.

- The limited supply of Td vaccine needs to be preserved for those with a **specific contraindication to pertussis-containing vaccines**.

- (ACIP VFC Vote) For children <7 years who develop a contraindication to DTaP, vaccine providers may administer Td for all recommended remaining doses in place of DTaP

**CDC Vaccines and Preventable Diseases (VPD): Diphtheria, Tetanus, and Pertussis Vaccine Recommendations**
Change to Pfizer Diluent

- Pfizer has changed the diluent pack size associated with CDC orders of Pfizer COVID-19 Vaccine (2023-2024 Formula) for ages 6 months through 4 years of age [59267-4315-02; COVID-19(Pfizer);(6m-4y); MDV3;10-pk].
- **Pfizer is now supplying diluent in a 25-pack.**
  - Previously vaccine orders for this presentation were supplied with diluent in a 10-pack.
- Please note: One vial of diluent is required to reconstitute one multidose vial of vaccine for individuals 6 months through 4 years of age.
- For questions about diluent received with Pfizer COVID-19 Vaccine (2023-2024 Formula) for ages 6 months through 4 years of age, please contact Pfizer customer service at: 1-800-666-7248, or mrnavaccines@pfizer.com.

<table>
<thead>
<tr>
<th>Total Doses of Vaccine</th>
<th>Total Vials of Vaccine</th>
<th>Diluent Supplied</th>
<th>Number of Diluent Vials to be shipped</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 doses</td>
<td>10</td>
<td>1 pack of 25 vials</td>
<td>25</td>
</tr>
<tr>
<td>60 doses</td>
<td>20</td>
<td>1 pack of 25 vials</td>
<td>25</td>
</tr>
<tr>
<td>90 doses</td>
<td>30</td>
<td>2 pack of 25 vials</td>
<td>50</td>
</tr>
<tr>
<td>120 doses</td>
<td>40</td>
<td>2 pack of 25 vials</td>
<td>50</td>
</tr>
</tbody>
</table>
New Presentation and National Drug Code (NDC) for Hiberix

• The prior presentation of Hiberix (NDC 58160-0818-11, one vial of lyophilized antigen and one vial of diluent) is no longer available.

• It has been replaced with a new presentation of Hiberix (NDC 58160-0726-15, **one vial of lyophilized antigen and one prefilled syringe of diluent**) and has been made available for ordering through the VFC order form as of March 1, 2024.

• Please continue to use any remaining doses of the prior presentation of Hiberix before using the new presentation to ensure doses are not wasted.
Inactivated VFC Providers Due to Delinquent 2024 VFC Recertification

• 47 VFC Providers have been inactivated for not submitting their 2024 VFC Recertification.
  o Due date was January 31, 2024, and multiple reminder communications have been sent.

• Medi-Cal and CHDP will be notified.

• If these providers are interested in enrolling in the VFC Program again, they can re-enroll during the next Recertification cycle in early 2025.

<table>
<thead>
<tr>
<th>County</th>
<th># of Providers</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAMEDA</td>
<td>2</td>
</tr>
<tr>
<td>CONTRA COSTA</td>
<td>1</td>
</tr>
<tr>
<td>FRESNO</td>
<td>1</td>
</tr>
<tr>
<td>LAKE</td>
<td>1</td>
</tr>
<tr>
<td>LOS ANGELES</td>
<td>15</td>
</tr>
<tr>
<td>MARIN</td>
<td>2</td>
</tr>
<tr>
<td>ORANGE</td>
<td>9</td>
</tr>
<tr>
<td>PLACER</td>
<td>1</td>
</tr>
<tr>
<td>RIVERSIDE</td>
<td>2</td>
</tr>
<tr>
<td>SAN BERNARDINO</td>
<td>3</td>
</tr>
<tr>
<td>SAN DIEGO</td>
<td>2</td>
</tr>
<tr>
<td>SAN MATEO</td>
<td>1</td>
</tr>
<tr>
<td>SANTA BARBARA</td>
<td>1</td>
</tr>
<tr>
<td>SANTA CLARA</td>
<td>4</td>
</tr>
<tr>
<td>TULARE</td>
<td>1</td>
</tr>
<tr>
<td>YOLO</td>
<td>1</td>
</tr>
<tr>
<td><strong>Grand Total</strong></td>
<td><strong>47</strong></td>
</tr>
</tbody>
</table>
Poll: CAIR Naming: COVID-19 Vaccine Group

**Question:** What should CAIR name the new COVID-19 vaccine group under the recommendations section of CAIR?

- [ ] COVID-19 Annual
- [ ] COVID-19 Seasonal
- [ ] COVID-19 Updated
Vaccine Management
Amy Pine, My Turn, and Maria Volk, myCAvax
Clinic Managers and patients will be able to access the Super Clinic functionality with the My Turn R48 release on Tuesday, March 26, 2024.
Patients will be able to schedule two or more appointments using the Super Clinic functionality.

Clinic Managers will be able to create Super Clinics and manage clinic inventory using the Super Clinic functionality.

Clinic Managers will be able to create Super Clinics and manage clinic inventory using the Super Clinic functionality.
Clinic Activation Reminder

Please ensure that your clinics are active for public appointments if you offer public scheduling. Log in to the system, navigate to the ‘Clinics’ tab and click the ‘Activate Location’ toggle on the clinic to display it on the public appointment booking website.
Known Issues

Missing ‘View More’ Button in the Knowledge Center
✓ When a Clinic Manager or Vaccine Administrator attempted to access the ‘All About My Turn’ section of the Knowledge Center, we noticed that we were missing some knowledge articles. These articles were hidden behind the missing ‘View More’ button. We worked to get the button back on the page to get access to the rest of the articles.

Workaround / Next Steps
✓ Fixed: Wednesday, February 28, 2024
VFA and LHD 317 Programs Now Live in myCAvax!

VFA / LHD 317 Program
Go Live: February 20, 2024
Release Highlights

All providers must:
✓ Enter the storage unit’s brand, model, the thermometer’s model, and serial number and specify the vaccine stored (by Program name) in the unit while updating storage unit records
✓ Have at least one backup thermometer entered in the system while creating / updating storage units

All providers can:
✓ View the new warning message to upload the thermometer’s certificate of calibration in the ‘Uploaded Documents’ tab when updating the thermometer type, model, serial number, or calibration expiration date
✓ View the updated ‘Returns and Waste’ label on the options / buttons instead of ‘Waste’
✓ View the ‘Inventory On-Hand’ group header updated to ‘Accountability’ under the ‘On-Hand Inventory’ tab on vaccine order records
✓ Receive email communications when the thermometer’s calibration expiration date is due or has passed the due date
✓ Use the new and updated multi-line transfer entry form introducing the new ‘Transport Container’ feature enabling them to enter multiple products in a single transfer entry

Providers enrolled in the Vaccines for Adults (VFA) / LHD 317 program can:
✓ View the new ‘Vaccines for Adults / LHD 317’ program tile on the home page
✓ Begin recertification by clicking the ‘Recertify Locations’ button visible in the ‘Vaccines for Adults / LHD 317’ program tile
✓ Enter / submit VFA / LHD 317 vaccine orders on the ‘VFA / 317 Order Request’ page; only one order can be placed during an ordering period
   ☑ Note: Vaccine orders in the ‘Draft’ and ‘Corrections Needed’ statuses expire automatically after 14 days from the last modified date.
✓ Enter VFA / LHD 317 Returns and Waste Events on the ‘VFA / LHD 317 Returns and Waste Events’ page
✓ Enter VFA / LHD 317 Excursions on the ‘VFA / LHD 317 Excursions’ page
✓ Enter VFA / LHD 317 Shipment Incidents on the ‘VFA / LHD 317 Shipment Incidents’ page
✓ Enter VFA / LHD 317 Vaccine Transfers on the ‘VFA / LHD 317 Transfers’ page

What’s New in myCAvax? – Release 45 (1 of 2)

New updates for providers launched on Tuesday, February 20, 2024!
New updates for providers launched on Tuesday, February 20, 2024!

Release Highlights

Providers enrolled in the VFA / LHD 317 program can:

✓ Receive email communications when the order gets approved or requires corrections
✓ Update and resubmit a vaccine order when the ‘Corrections Needed’ status has been set by the Customer Service Representative (CSR) following their review
✓ View the new ‘Total Order Cost’ field on the ‘Order and Transfer Item’ records
Great work! **33%** of VFA-eligible providers completed recertification so far.

As of **Thursday, March 7, 2024**, **180** VFA-eligible providers have completed recertification, out of **537** total providers eligible for VFA.
Workarounds to Complete Recertification Part Two

Issues

Missing LHD 317 / VFA tile on the Landing Page

Workaround / Next Steps

✓ If you do not see the LHD 317 or VFA tile on the landing page and you are the Primary VFA Contact or LHD 317 Vaccine Coordinator, contact the Provider Call Center.
Navigating to the Provider Location Account

Follow the steps below to navigate to your Provider Location and update storage units.

1. Navigate to the ‘Program Locations’ page.
2. Select ‘View Program Location’.
3. Select the ‘Account Name’.
4. Select the ‘Related’ tab and scroll until you see storage capacities.

Check out the ‘Managing Storage Units’ job aid in the Knowledge Center to learn more.
Next Steps: Updating / Adding Storage Units for VFA

Providers will be required to update / add storage units during recertification.

If you have not yet completed recertification...
Update existing storage units by viewing historical data and copying appropriate information.

If you have already completed recertification, log in to myCAvax and make updates to existing storage units. Navigate to your Location Account and select the ‘Related’ tab to find the storage capacity section.
Action Required: Update Storage Units

All providers must update the storage units associated with their Provider Location. You will need to indicate what program vaccines are stored in the unit and update required thermometer and storage unit information.

If you do not update your storage unit information, transfers will not function properly for the following programs: VFA, LHD 317, BAP, and Outbreak.
If you have questions regarding the 317 or VFA program requirements or the myCAvax system, contact the Provider Call Center at (833) 502-1245 or providercallcenter@cdph.ca.gov, Mon–Fri, 8:00 AM – 5:00 PM PT.
Previously Recorded VFA Trainings: EZIZ Links

The slides and recording of the ‘VFA 101 Recertification and Vaccine Ordering in myCAvax’ session hosted on Thursday, February 22, 2024, are available on EZIZ.

The slides and recording of the ‘VFA 102 Vaccine Inventory Management in myCAvax’ session hosted on Thursday, February 29, 2024, are available on EZIZ.
Vaccine Inventory Management Job Aids

The job aids linked below detail how to complete vaccine inventory reports in myCAvax. You can also access these job aids from the Knowledge Center (myCAvax login required).

<table>
<thead>
<tr>
<th>Vaccine Inventory Management Job Aids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recording Shipment Incidents</td>
</tr>
<tr>
<td>Recording Temperature Excursions</td>
</tr>
<tr>
<td>Recording Returns and Waste</td>
</tr>
<tr>
<td>Recording a Vaccine Transfer</td>
</tr>
</tbody>
</table>
Bridge Access Program (BAP): Vaccine Allocations Cadence Update

Allocations of BAP COVID-19 vaccine products are refreshed on a biweekly cadence. CDPH receives allocations mid-week and distributes inventory to the LHDs within a few business days.

The most recent CDC allocation refresh was received Wednesday, February 28, 2024. Doses were added to LHD allocations on Thursday, February 29, 2024.
Starting the week of **January 29, 2024**, CDPH began holding back doses to keep on reserve for LHDs with higher demand in their county. LHDs can reach out to the Ordering Leads via chatter (@orderingleads) on myCAvax with questions related to BAP COVID-19 vaccine orders or allocations. LHDs may submit off-cycle allocation requests to the Ordering Leads with a rationale behind their need.

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial Allocation to LHJ’s</td>
<td>279,790</td>
</tr>
<tr>
<td>Reserve</td>
<td>100,210</td>
</tr>
<tr>
<td>Total State Allocation</td>
<td>380,000</td>
</tr>
</tbody>
</table>

**Comirnaty**
- Doses Received: 33,080
- State Allocation: 162,260

**Spikevax**
- Doses Received: 86,580
- State Allocation: 111,990

**Novavax**
- Doses Received: 4,490
- State Allocation: 5,600
Slide Icon Key

<table>
<thead>
<tr>
<th>Icon</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>🌟</td>
<td>This is to label slides that are referencing upcoming or existing functionality and how to use it in the system.</td>
</tr>
<tr>
<td>🛒</td>
<td>This is to label slides that include important system reminders.</td>
</tr>
<tr>
<td>💡</td>
<td>This is to label slides that include tips and best practices to improve your system experience.</td>
</tr>
</tbody>
</table>

Have suggestions to improve My Turn or myCAvax? Leave a comment in our [feedback form](#).
VFA Webinar – Register Now!

Audience: Identified VFA Key Practice Staff + Medical Staff for Adult Patient Population

Wednesday, March 13, 2024, 12 – 1PM PST

Topics: Program Updates, ACIP Update, and a Peer-to-Peer sharing opportunity to hear about Best Practices from Golden Valley Health Centers

REGISTER NOW!
Complete your Recertification ASAP!

- As of March 7, 180 VFA Sites have completed Recertification
- **Recertification Worksheet** Now Available
- Recertification must be completed to have access to April Vaccine Ordering
- Recertification must be completed to have access to Vaccine Management Functions (Reporting Transfers, Returns, Waste, Excursions)
- Questions? Contact the Provider Call Center
  - Email: ProviderCallCenter@cdph.ca.gov
  - Phone: (833) 502 – 1245
    Open Monday – Friday, 8AM – 5PM
VFA Recertification Part 2

CDPH has prepared a worksheet to gather the required information that you will input into myCAvax to complete recertification “part two.” Please download from EZIZ and use the worksheet to prepare. If the information gathered from recertification “part one” in MyVFCvaccines is identical to your VFA program, much of that can be inputted into myCAvax.

<table>
<thead>
<tr>
<th>Practice Name</th>
<th>McEvan ID</th>
<th>EIN</th>
<th>Registry ID</th>
</tr>
</thead>
</table>

**Step 1 – Practice Information/Hiring**

<table>
<thead>
<tr>
<th>Practice Information/Hiring Address (No P.O. Box)</th>
<th>City</th>
<th>ZIP</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>EIN Type Registration Number (ISN)</th>
<th>ISN</th>
</tr>
</thead>
</table>

**Step 2 – Key Practice Staff**

<table>
<thead>
<tr>
<th>Role/Responsibility</th>
<th>Name</th>
<th>Title</th>
<th>Specialty/Clinic Title</th>
<th>National Provider ID</th>
<th>Medical License #</th>
<th>Direct Phone Number</th>
<th>Email for program updates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provider of Record</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccine Coordinator</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back Up Vaccine Coordinator</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provider of Record Designee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additional Staff Members</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

California Department of Public Health Immunization Branch

IWAM 041 (07/14) Page 1 of 8
VFA Recertification Training

For California VFA Recertification:

<table>
<thead>
<tr>
<th>Required for Vaccine Coordinator, Backup, Provider of Record and Designee</th>
</tr>
</thead>
<tbody>
<tr>
<td>VFA Program Requirements Completed 02/21/2024 Certificate Review</td>
</tr>
</tbody>
</table>

For California LHD 317 Program Recertification:

<table>
<thead>
<tr>
<th>Required for Vaccine Coordinator, Backup, Provider of Record and Designee</th>
</tr>
</thead>
<tbody>
<tr>
<td>LHD 317 Program Requirements Completed 02/21/2024 Certificate Review</td>
</tr>
</tbody>
</table>

VFA providers are to complete the required EZIZ training as soon as possible. CDPH will be reviewing to confirm training completion.

Be sure to complete the required for your designated program
Resources and Q&A

Leslie Amani, CDPH
Vaccine Support

Provider Call Center
Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAvax Help Desk inquiries: myCAvax.hd@cdph.ca.gov
- For My Turn Clinic Help Desk inquiries: MyTurn.Clinic.HD@cdph.ca.gov
- For all other inquiries: providercallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM

myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below.
COVID-19 Provider FAQs

Answers to providers’ COVID-19 vaccine and therapeutics questions, updated 3/7/2024!

Q: What is the recommended COVID-19 vaccine schedule for adults age 65 years and older?

A: CDC now recommends that all adults ages 65 years and older receive an additional updated 2023-2024 COVID-19 vaccine dose to help protect against severe disease from COVID-19. For more information, see CDC’s Interim Clinical Considerations guidance, as well as the CDPH Updated Timing Guide (Spanish version).

Q: Does diluent for Pfizer COVID-19 vaccine for patients 6 months – 4 years of age need to be ordered separately or does it come with the vaccine?

A: Pfizer will provide diluent with their commercial and VFC vaccines indicated for patients 6 months - 4 years of age. Pfizer has changed the diluent pack size associated with CDC orders of Pfizer COVID-19 Vaccine (2023-2024 Formula) for ages 6 months through 4 years of age [59267-4315-02; COVID-19(Pfizer)];[6m-4y];MDV3;10-pk).

Previously vaccine orders for this presentation were supplied with diluent in a 10-pack. Pfizer will now supply diluent in a 25-pack. Please note: One vial of diluent is required to reconstitute one multidose vial of vaccine for individuals 6 months through 4 years of age.
# CDPH Provider Webinars and Trainings

## Week of March 11, 2024

<table>
<thead>
<tr>
<th>Monday 3/11</th>
<th>Tuesday 3/12</th>
<th>Wednesday 3/13</th>
<th>Thursday 3/14</th>
<th>Friday 3/15</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Live Webinars and Training</strong></td>
<td><strong>Live Webinars and Training</strong></td>
<td><strong>Live Webinars and Training</strong></td>
<td><strong>Live Webinars and Training</strong></td>
<td><strong>Live Webinars and Training</strong></td>
</tr>
<tr>
<td>CA Immunization Coalition (CIC) Ed Hour: Back to the Vax: A Guide to Innoculating Yourself Against Anti-Vax Propaganda 12:00 pm – 1:00 pm</td>
<td>VFA Webinar: 2024 ACIP Updates &amp; Best Practices for Adult Immunizations 12:00 pm – 1:00 pm</td>
<td></td>
<td></td>
<td>No Friday Webinar</td>
</tr>
<tr>
<td><strong>View On Demand</strong></td>
<td><strong>View On Demand</strong></td>
<td><strong>View On Demand</strong></td>
<td><strong>View On Demand</strong></td>
<td><strong>View On Demand</strong></td>
</tr>
<tr>
<td>• CDPH Weekly Provider Archived Webinars and Slides</td>
<td>• Introduction to My Turn Onboarding (v. 1/4/22)</td>
<td>• Moderna COVID-19 Vaccine Resources for Providers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• COVID-19 Crucial Conversations Archived Webinars and Slides</td>
<td>• Latest Features in My Turn (Requires myCAvax Login)</td>
<td>• CDC COVID-19 Vaccination Clinical &amp; Professional Resources</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• AIM Vaccine Confidence Toolkit Webinar Series</td>
<td>• myCAvax Release Notes for LHD and CDPH Users (Requires myCAvax Login)</td>
<td>• Novavax COVID-19 Vaccine Information</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pfizer COVID-19 Vaccine (COMIRNATY) Information</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Help Desk**

*CDPH Provider Call Center: 1-833-502-1245, M-F 8am-5pm Email: providercallcenter@cdph.ca.gov*

**My Turn:** Help Desk Email: myturn.clinic.hd@cdph.ca.gov Onboarding Email: myturnonboarding@cdph.ca.gov

**myCAvax:** Help Desk Email: mycavax.hd@cdph.ca.gov

**Mpox:** Email: stdcb@cdph.ca.gov

## Immunization Resources

- California’s General Immunization Resources (eziz.org)
- RSV Immunization Resources
- Flu Vaccination Resources
- COVID-19 Vaccination Resources
- COVID-19 Treatments
- Mpox Vaccination Resources
## CDPH Provider Webinars and Trainings

### Week of March 18, 2024 - DRAFT

<table>
<thead>
<tr>
<th>Live Webinars and Training</th>
<th>On Demand</th>
<th>Help</th>
<th>Immunization Resources</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday 3/18</td>
<td>Tuesday 3/19</td>
<td>Wednesday 3/20</td>
<td>Thursday 3/21</td>
</tr>
<tr>
<td>• CDPH Weekly Provider Archived Webinars and Slides</td>
<td>• COVID-19 Crucial Conversations Archived Webinars and Slides</td>
<td>• AIM Vaccine Confidence Toolkit Webinar Series</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Help Desk**

*CDPH Provider Call Center: 1-833-502-1245, M-F 8am-5pm*

My Turn: Help Desk Email: myturn.clinic.hd@cdph.ca.gov

myCAvax: Help Desk Email: mycavax.hd@cdph.ca.gov

Mpox: Email: stdcb@cdph.ca.gov

**Immunization Resources**

- California’s General Immunization Resources (eziz.org)
- RSV Immunization Resources
- Flu Vaccination Resources
- COVID-19 Vaccination Resources
- COVID-19 Treatments
- Mpox Vaccination Resources
California’s Digital Vaccine Record (DVR)

Welcome to the Digital Vaccine Record (DVR) portal

To get a digital copy of your vaccine record, just enter a few details below. You can get a link to your COVID-19 Vaccine Record with a QR code or your California Immunization Record. Save it on your phone and use it as proof of vaccination wherever you go.

If you are a parent or guardian and have multiple vaccine records associated with a single cell phone number or email address, enter each Digital Vaccine Record request separately.

NOTE: It is possible that some or all vaccine doses you received were not reported to the California Immunization Registry (CAIR), and therefore your Digital Vaccine Record may not be complete. If your record is incomplete, please ask your provider to submit your vaccine information to CAIR so we can update your record. It’s important that you provide up to date information about yourself (phone, email, first and last name) to your provider so you can access your complete record.

If you received your vaccinations from a federal agency (e.g., Department of Defense, Indian Health Services, or Veterans Affairs), you may need to contact those agencies for assistance with your vaccination record.

If you have questions about your vaccination record, visit our FAQ.
## COVID-19 Therapeutics Resources

<table>
<thead>
<tr>
<th>Type of Support</th>
<th>Description</th>
<th>Updated 2.1.24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Guidance</td>
<td>For general Therapeutics questions, please email: <a href="mailto:COVIDRxProviders@cdph.ca.gov">COVIDRxProviders@cdph.ca.gov</a></td>
<td></td>
</tr>
<tr>
<td>General Information</td>
<td>CDPH COVID-19 Treatments Webpage (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CDPH COVID-19 Treatments Job Aid (questions and answers for the public on COVID-19 therapeutics)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>COVID-19 Therapeutics Best Practices Checklist (testing, prescribing, dispensing, and more)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frequently Asked Questions document for clinics, providers, and pharmacists</td>
<td></td>
</tr>
<tr>
<td>Locating Resources</td>
<td>Finding Providers and Test-to-Treat Sites</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• COVID-19 Therapeutics Locator (arcgis.com)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Test-to-Treat (hhs.gov)</td>
<td></td>
</tr>
<tr>
<td>LHJ Therapeutics</td>
<td>Primary source for recorded webinars, slides, datasets and HPOP reporting information. (For access, email <a href="mailto:JEOCuser54@cdph.ca.gov">JEOCuser54@cdph.ca.gov</a>)</td>
<td></td>
</tr>
<tr>
<td>SharePoint</td>
<td>• Therapeutic Weekly Email Update files (SharePoint)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• CDPH Therapeutics_HPoP Account Verification &amp; Reporting information</td>
<td></td>
</tr>
<tr>
<td>Questions</td>
<td>For general CDPH Therapeutics questions, please email <a href="mailto:COVIDRxProviders@cdph.ca.gov">COVIDRxProviders@cdph.ca.gov</a></td>
<td></td>
</tr>
<tr>
<td></td>
<td>For ordering, program inquiries, signing up new HPOP Accounts: please e-mail <a href="mailto:CDPHTherapeutics@cdph.ca.gov">CDPHTherapeutics@cdph.ca.gov</a></td>
<td></td>
</tr>
</tbody>
</table>
During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.

Note: CDPH SMEs and Panelists on today’s call will do their best to answer all questions related to today’s updates.
Upcoming CDPH Webinar Opportunity

CDPH Immunization Updates for Providers
Next session: Friday, March 22, 2024
9AM – 10:30AM